Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer

Bioscience, Biotechnology and Biochemistry

Volumn 72, Issue 6, 2008, Pages 1586-1594

  Chen, Chien Ho ^a   Liu, Der Zen ^a   Fang, Hsu Wei ^b   Liang, Hong Jen ^c   Yang, Tzu Sheng ^b   Lin, Shyr Yi ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

Author keywords

Arg Gly Asp (RGD); Gastric cancer; Liposome; Octreotide; Xenograft

Indexed keywords

AUSTENITE; CELL DEATH; CELL GROWTH; CELLS; DRUG DELIVERY; DRUG DOSAGE; ETHYLENE GLYCOL; FREE VOLUME; GLYCOLS; LIPOSOMES; PHOTOACOUSTIC EFFECT; POLYETHYLENE GLYCOLS; TARGETS; TUMORS;

ARG GLY ASP (RGD); CELL SURVIVALS; CLINICAL APPLICATIONS; CYTOTOXIC EFFECTS; DIMETHYL-SULFOXIDE (DMSO); GASTRIC CANCERS; IN-VITRO; IN-VIVO; MULTI-TARGET; NUDE MICE; OCTREOTIDE; POLYETHYLENE GLYCOL (PEG); TUMOR GROWTH; TUMOR VOLUMES;

CHEMOTHERAPY;

ANDROSTANOLONE; ANTINEOPLASTIC AGENT; LIPOSOME;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; HUMAN; MALE; MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 45849104166     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.80096     Document Type: Article

References (41)

1. Chen, T. H., Hsu, Y. T., Chen, C. H., Kao, S. H., and Lee, H. M., Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. Mitochondrion, 7, 101-105 (2007).
2. Wang, N., Luo, H. W., Niwa, M., and Ji, J., A new platelet aggregation inhibitor from Salvia miltiorrhiza. Planta Med., 55, 390-391 (1989).
3. Park, E. J., Zhao, Y. Z., Kim, Y. C., and Sohn, D. H., PF2401-SF, standardized fraction of Salvia miltiorrhiza and its constituents, tanshinone I, tanshinone IIA, and cryptotanshinone, protect primary cultured rat hepatocytes from bile acid-induced apoptosis by inhibiting JNK phosphorylation. Food Chem. Toxicol., 45, 1891-1898 (2007).
4. Wang, X., Bastow, K. F., Sun, C. M., Lin, Y. L., Yu, H. J., Don, M. J., Wu, T. S., Nakamura, S., and Lee, K. H., Antitumor agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J. Med. Chem., 47, 5816-5819 (2004).
5. Liu, J., Shen, H. M., and Ong, C. N., Salvia miltiorrhiza inhibits cell growth and induces apoptosis in human hepatoma HepG(2) cells. Cancer Lett., 153, 85-93 (2000).
6. Franek, K. J., Zhou, Z., Zhang, W. D., and Chen, W. Y., In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent. Int. J. Oncol., 26, 217-224 (2005).
7. Lee, D.-S., Lee, S.-H., Kwon, G.-S., Lee, H.-K., Woo, J.-H., Kim, J.-G., and Hong, S.-D., Inhibition of DNA topoisomerase I by dihydrotanshinone I, components of a medicinal herb Salvia miltiorrhiza Bunge. Biosci. Biotechnol. Biochem., 63, 1370-1373 (1999).
8. Lee, D. S., and Lee, S. H., Biological activity of dihydrotanshinone I: effect on apoptosis. J. Biosci. Bioeng., 89, 292-293 (2000).
9. Sessa, G., and Weissmann, G., Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res., 9, 310-318 (1968).
10. Weinstein, J. N., and Leserman, L. D., Liposomes as drug carriers in cancer chemotherapy. Pharmacol. Ther., 24, 207-233 (1984).
11. Swenson, C. E., Bolcsak, L. E., Batist, G., Guthrie, T. H., Jr., Tkaczuk, K. H., Boxenbaum, H., Welles, L., Chow, S. C., Bhamra, R., and Chaikin, P., Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs, 14, 239-246 (2003).
12. Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., and Winer, E., Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94, 25-36 (2002).
13. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L., Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett., 268, 235-237 (1990).
14. Leserman, L. D., Barbet, J., Kourilsky, F., and Weinstein, J. N., Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature, 288, 602-604 (1980).
15. Leserman, L. D., Weinstein, J. N., Moore, J. J., and Terry, W. D., Specific interaction of myeloma tumor cells with hapten-bearing liposomes containing methotrexate and carboxyfluorescein. Cancer Res., 40, 4768-4774 (1980).
16. Torchilin, V. P., Klibanov, A. L., Huang, L., O'Donnell, S., Nossiff, N. D., and Khaw, B. A., Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J., 6, 2716-2719 (1992).
17. Blume, G., Cevc, G., Crommelin, M. D., Bakker-Woudenberg, I. A., Kluft, C., and Storm, G., Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta, 1149, 180-184 (1993).
18. Torchilin, V. P., Levchenko, T. S., Lukyanov, A. N., Khaw, B. A., Klibanov, A. L., Rammohan, R., Samokhin, G. P., and Whiteman, K. R., p-Nitrophenyl-carbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta, 1511, 397-411 (2001).
19. Murray, C. J., and Lopez, A. D., Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 349, 1498-1504 (1997).
20. Pisani, P., Parkin, D. M., Bray, F., and Ferlay, J., Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999).
21. Cli, F., Celik, I., Aykan, F., Uner, A., Demirkazik, A., Ozet, A., Ozguroglu, M., Tas, F., Akbulut, H., and Firat, D., A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer, 83, 2475-2480 (1998).
22. Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., and Pless, J., SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci., 31, 1133-1140 (1982).
23. Lamberts, S. W., Oosterom, R., Neufeld, M., and del Pozo, E., The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J. Clin. Endocrinol. Metab., 60, 1161-1165 (1985).
24. Miller, G. V., Farmery, S. M., Woodhouse, L. F., and Primrose, J. N., Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br. J. Cancer, 66, 391-395 (1992).
25. Szepeshazi, K., Schally, A. V., Nagy, A., Wagner, B. W., Bajo, A. M., and Halmos, G., Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer, 98, 1401-1410 (2003).
26. Brooks, P. C., Role of integrins in angiogenesis. Eur. J. Cancer, 32A, 2423-2429 (1996).
27. Stromblad, S., Becker, J. C., Yebra, M., Brooks, P. C., and Cheresh, D. A., Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J. Clin. Invest., 98, 426-433 (1996).
28. Stromblad, S., and Cheresh, D. A., Integrins, angiogenesis and vascular cell survival. Chem. Biol., 3, 881-885 (1996).
29. Chung, T. W., Yang, M. G., Liu, D. Z., Chen, W. P., Pan, C. I., and Wang, S. S., Enhancing growth human endothelial cells on Arg-Gly-Asp (RGD) embedded poly (epsilon-caprolactone) (PCL) surface with nanometer scale of surface disturbance. J. Biomed. Mater. Res. A, 72, 213-219 (2005).
30. Ho, Y. S., Wu, C. H., Chou, H. M., Wang, Y. J., Tseng, H., Chen, C. H., Chen, L. C., Lee, C. H., and Lin, S. Y., Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways. Food Chem. Toxicol., 43, 1483-1495 (2005).
31. Osborne, C. K., Coronado, E. B., and Robinson, J. P., Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23, 1189-1196 (1987).
32. Lee, W. S., Chen, R. J., Wang, Y. J., Tseng, H., Jeng, J. H., Lin, S. Y., Liang, Y. C., Chen, C. H., Lin, C. H., Lin, J. K., Ho, P. Y., Chu, J. S., Ho, W. L., Chen, L. C., and Ho, Y. S., In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest. Int. J. Cancer, 106, 125-137 (2003).
33. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., and Stein, H., Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 133, 1710-1715 (1984).
34. Inda, A. M., Andrini, L. B., Garcia, M. N., Garcia, A. L., Fernandez Blanco, A., Furnus, C. C., Galletti, S. M., Prat, G. D., and Errecalde, A. L., Evaluation of angiogenesis with the expression of VEGF and CD34 in human non-small cell lung cancer. J. Exp. Clin. Cancer Res., 26, 375-378 (2007).
35. Huang, C. M., Wu, Y. T., and Chen, S. T., Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol., 7, 453-461 (2000).
36. Koning, G. A., Schiffelers, R. M., Wauben, M. H., Kok, R. J., Mastrobattista, E., Molema, G., ten Hagen, T. L., and Storm, G., Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum., 54, 1198-1208 (2006).
37. Xiong, X. B., Huang, Y., Lu, W. L., Zhang, X., Zhang, H., Nagai, T., and Zhang, Q., Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci., 94, 1782-1793 (2005).
38. Xiong, X. B., Huang, Y., Lu, W. L., Zhang, X., Zhang, H., Nagai, T., and Zhang, Q., Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J. Control. Release, 107, 262-275 (2005).
39. Zhang, Z. W., Patchett, S. E., and Farthing, M. J., Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs, 11, 757-764 (2000).
40. Ikegami, T., Matsuzaki, Y., Al Rashid, M., Ceryak, S., Zhang, Y., and Bouscarel, B., Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol. Cancer Ther., 5, 68-79 (2006).
41. Morris, E. J., and Geller, H. M., Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol., 134, 757-770 (1996).